Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement
The submission marks another key milestone in the agreement for which Mithra will receive a EUR 2.5 million milestone payment.
- The submission marks another key milestone in the agreement for which Mithra will receive a EUR 2.5 million milestone payment.
- Fuji Pharma obtained the right to commercialize both ESTELLE® and DONESTA® in Japan and the ASEAN region in 2016, targeting a potential market of 330 million patients.
- David Horn Solomon, CEO at Mithra: “We are very proud of our partnership with Fuji Pharma and today’s announcement marks another key milestone in Mithra’s drive for growth and achieving its mission.
- The global dysmenorrhea market was worth EUR 257 million in 20221.